180 related articles for article (PubMed ID: 17215146)
1. RNA targeted therapeutics for hematologic malignancies.
Gewirtz AM
Blood Cells Mol Dis; 2007; 38(2):117-9. PubMed ID: 17215146
[TBL] [Abstract][Full Text] [Related]
2. Nucleic acid therapeutics for hematologic malignancies--theoretical considerations.
Opalinska JB; Kalota A; Chattopadhyaya J; Damha M; Gewirtz AM
Ann N Y Acad Sci; 2006 Oct; 1082():124-36. PubMed ID: 17145934
[TBL] [Abstract][Full Text] [Related]
3. Stimulation of the immune system by therapeutic antisense oligodeoxynucleotides and small interfering RNAs via nucleic acid receptors.
Richardt-Pargmann D; Vollmer J
Ann N Y Acad Sci; 2009 Sep; 1175():40-54. PubMed ID: 19796076
[TBL] [Abstract][Full Text] [Related]
4. Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA.
Mahato RI; Cheng K; Guntaka RV
Expert Opin Drug Deliv; 2005 Jan; 2(1):3-28. PubMed ID: 16296732
[TBL] [Abstract][Full Text] [Related]
5. Chemical modification of gene silencing oligonucleotides for drug discovery and development.
Chen X; Dudgeon N; Shen L; Wang JH
Drug Discov Today; 2005 Apr; 10(8):587-93. PubMed ID: 15837602
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of antisense nucleic acid molecules.
Opalinska JB; Gewirtz AM
Sci STKE; 2003 Oct; 2003(206):pe47. PubMed ID: 14583589
[TBL] [Abstract][Full Text] [Related]
7. Oral delivery of siRNA and antisense oligonucleotides.
Akhtar S
J Drug Target; 2009 Aug; 17(7):491-5. PubMed ID: 19530907
[TBL] [Abstract][Full Text] [Related]
8. Myb targeted therapeutics for the treatment of human malignancies.
Gewirtz AM
Oncogene; 1999 May; 18(19):3056-62. PubMed ID: 10378701
[TBL] [Abstract][Full Text] [Related]
9. Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies.
Shigdar S; Ward AC; De A; Yang CJ; Wei M; Duan W
Br J Haematol; 2011 Oct; 155(1):3-13. PubMed ID: 21810089
[TBL] [Abstract][Full Text] [Related]
10. Synthetic nucleic acids as potential therapeutic tools for treatment of bladder carcinoma.
Fuessel S; Meye A; Kraemer K; Kunze D; Hakenberg OW; Wirth MP
Eur Urol; 2007 Feb; 51(2):315-26; discussion 326-7. PubMed ID: 16935415
[TBL] [Abstract][Full Text] [Related]
11. Antisense oligonucleotides for haematological malignancies.
Cotter FE
Haematologica; 1999 Jun; 84 Suppl EHA-4():19-22. PubMed ID: 10907458
[No Abstract] [Full Text] [Related]
12. Challenges and opportunities for local and systemic delivery of siRNA and antisense oligonucleotides.
Sepp-Lorenzino L; Ruddy M
Clin Pharmacol Ther; 2008 Nov; 84(5):628-32. PubMed ID: 18800034
[No Abstract] [Full Text] [Related]
13. The efficiency of CD40 down regulation by siRNA and antisense ODN: comparison of lipofectamine and FuGENE6.
Ebadi P; Karimi MH; Pourfathollah AA; Saheb Ghadam Lotfi A; Soheili ZS; Samiee S; Hajati S; Nadali F; Geramizadeh B; Moazzeni SM
Iran J Immunol; 2009 Mar; 6(1):1-11. PubMed ID: 19293472
[TBL] [Abstract][Full Text] [Related]
14. Antisense oligonucleotides, aptamers and SiRNA: promises for the treatment of ocular diseases.
Fattal E; Bochot A
Arch Soc Esp Oftalmol; 2006 Jan; 81(1):3-4, 5-6. PubMed ID: 16450253
[No Abstract] [Full Text] [Related]
15. Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules.
Opalinska JB; Kalota A; Gifford LK; Lu P; Jen KY; Pradeepkumar PI; Barman J; Kim TK; Swider CR; Chattopadhyaya J; Gewirtz AM
Nucleic Acids Res; 2004; 32(19):5791-9. PubMed ID: 15514112
[TBL] [Abstract][Full Text] [Related]
16. Sugar boost: when ribose modifications improve oligonucleotide performance.
Faria M; Ulrich H
Curr Opin Mol Ther; 2008 Apr; 10(2):168-75. PubMed ID: 18386229
[TBL] [Abstract][Full Text] [Related]
17. Antisense oligodeoxynucleotide-conjugated hyaluronic acid/protamine nanocomplexes for intracellular gene inhibition.
Mok H; Park JW; Park TG
Bioconjug Chem; 2007; 18(5):1483-9. PubMed ID: 17602578
[TBL] [Abstract][Full Text] [Related]
18. Development of siRNA for therapeutics: efficient synthesis of phosphorothioate RNA utilizing phenylacetyl disulfide (PADS).
Ravikumar VT; Andrade M; Carty RL; Dan A; Barone S
Bioorg Med Chem Lett; 2006 May; 16(9):2513-7. PubMed ID: 16481168
[TBL] [Abstract][Full Text] [Related]
19. Targeted delivery of therapeutic oligonucleotides to pulmonary circulation.
Wilson A; He F; Li J; Ma Z; Pitt B; Li S
Adv Genet; 2005; 54():21-41. PubMed ID: 16096006
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic oligonucleotides.
Goodchild J
Methods Mol Biol; 2011; 764():1-15. PubMed ID: 21748630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
